Sökning: WFRF:(Gutierez Jorge) >
Final 10-year resul...
Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer
-
- Sonnenblick, Amir (författare)
- University of Libre Bruxelles, Belgium
-
- Francis, Prudence A. (författare)
- Peter MacCallum Cancer Centre, Australia; Australia and New Zealand Breast Cancer Trials Grp, Australia; Int Breast Cancer Study Grp, Switzerland
-
- Azim, Hatem A. Jr. (författare)
- University of Libre Bruxelles, Belgium
-
visa fler...
-
- de Azambuja, Evandro (författare)
- University of Libre Bruxelles, Belgium
-
- Nordenskjöld, Bo (författare)
- Linköpings universitet,Avdelningen för kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Onkologiska kliniken US
-
- Gutierez, Jorge (författare)
- Clin Las Condes, Chile
-
- Quinaux, Emmanuel (författare)
- Int Institute Drug Dev, Belgium
-
- Mastropasqua, Mauro G. (författare)
- University of Milan, Italy; University of Milan, Italy
-
- Ameye, Lieveke (författare)
- University of Libre Bruxelles, Belgium
-
- Anderson, Michael (författare)
- Copenhagen University Hospital, Denmark; Danish Breast Cancer Cooperat Grp, Denmark
-
- Lluch, Ana (författare)
- University of Valencia, Spain
-
- Gnant, Michael (författare)
- Medical University of Vienna, Austria; Medical University of Vienna, Austria
-
- Goldhirsch, Aron (författare)
- European Institute Oncol, Italy; Int Breast Cancer Study Grp, Switzerland
-
- Di Leo, Angelo (författare)
- Hospital Prato, Italy
-
- Barnadas, Agusti (författare)
- University of Autonoma Barcelona, Spain
-
- Cortes-Funes, Hernan (författare)
- University Hospital 12 Octubre, Spain
-
- Piccart, Martine (författare)
- University of Libre Bruxelles, Belgium
-
- Crown, John (författare)
- St Vincets University Hospital, Ireland
-
visa färre...
-
(creator_code:org_t)
- Elsevier, 2015
- 2015
- Engelska.
-
Ingår i: European Journal of Cancer. - : Elsevier. - 0959-8049 .- 1879-0852. ; 51:12, s. 1481-1489
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Aim: Breast International Group (BIG) 2-98 is a randomised phase III trial that tested the effect of adding docetaxel, either in sequence to or in combination with anthracycline-based adjuvant chemotherapy, in women with node-positive breast cancer (BC). Here, we present the 10-year final trial safety and efficacy analyses. We also report an exploratory analysis on the predictive value of Ki67 for docetaxel efficacy, in the BIG 2-98 and using a pooled analysis of three other randomised trials. Patients and methods: 2887 patients were randomly assigned in a 2 x 2 trial design to one of four treatments. The primary objective was to evaluate the overall efficacy of docetaxel on disease free survival (DFS). Secondary objectives included comparisons of sequential docetaxel versus sequential control arm, safety and overall survival (OS). Ki67 expression was centrally evaluated by immunohistochemistry. Results: After a median follow-up of 10.1 years, the addition of docetaxel did not significantly improve DFS or OS (hazard ratio (HR) = 0.91, 95% confidence interval (CI) = 0.81-1.04; P = 0.16 and HR = 0.88, 95% CI = 0.76-1.03; P = 0.11, respectively). Sequential docetaxel did not improve DFS compared to the sequential control arm (HR = 0.86, 95% CI = 0.721.03; P = 0.10). In oestrogen receptor (ER)-positive tumours with Ki67 greater than= 14%, the addition of docetaxel resulted in 5.4% improvement in 10-year OS (P = 0.03, test for interaction = 0.1). In a multivariate model, there was a trend for improved DFS and OS in ER-positive patients with high Ki67 and treated with docetaxel (HR = 0.79, 95% CI = 0.63-1.01; P = 0.05 and HR = 0.76, 95% CI = 0.57-1.01; P = 0.06, respectively). A pooled analysis of four randomised trials showed a benefit of taxanes in highly proliferative ER-positive disease but not in low proliferating tumours (interaction test P = 0.01). Conclusion: The DFS benefit previously demonstrated with sequential docetaxel is no longer observed at 10 years. However, an exploratory analysis suggested a benefit of docetaxel in patients with highly proliferative ER-positive BC.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine (hsv//eng)
Nyckelord
- Ki67; Adjuvant taxanes; ER positive; Breast cancer; Pooled analysis
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Sonnenblick, Ami ...
-
Francis, Prudenc ...
-
Azim, Hatem A. J ...
-
de Azambuja, Eva ...
-
Nordenskjöld, Bo
-
Gutierez, Jorge
-
visa fler...
-
Quinaux, Emmanue ...
-
Mastropasqua, Ma ...
-
Ameye, Lieveke
-
Anderson, Michae ...
-
Lluch, Ana
-
Gnant, Michael
-
Goldhirsch, Aron
-
Di Leo, Angelo
-
Barnadas, Agusti
-
Cortes-Funes, He ...
-
Piccart, Martine
-
Crown, John
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
- Artiklar i publikationen
-
European Journal ...
- Av lärosätet
-
Linköpings universitet